Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.
Open accessThe DOI matches its Crossref record; 656 of the 674 references it cites were found in a registry or an index; 285 of the 444 sources its claims cite were checked for support.
Abstract
Available drugs primarily offer symptomatic relief, while newer anti-amyloid therapies may have disease-modifying effects but still require long-term efficacy and safety validation.
Overview
CoChat Summary
TL;DR
This review synthesizes recent mechanistic, biomarker, clinical-trial, and drug-development advances in Alzheimer’s disease (AD), emphasizing that AD remains multifactorial and that no single hypothesis fully explains its progression. It highlights new FDA-approved disease-modifying antibodies and emerging drug-design strategies such as selective inhibitors, dual-target inhibitors, allosteric modulators, covalent inhibitors, PROTACs, and PPI modulators.
Key findings
- AD is described as a complex disease involving multiple overlapping hypotheses and pathways, including cholinergic, amyloid, tau, neuroinflammation, oxidative stress, metal dyshomeostasis, glutamatergic excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy.
- The review states that recent FDA approvals of aducanumab and lecanemab suggest potential disease-modifying effects, but their long-term efficacy and safety still need further validation.
- For biomarker-based diagnosis, the paper reports that amyloid PET has 90% sensitivity and specificity for diagnosing AD, and that P-tau181 is the most accurate CSF indicator for distinguishing AD from non-AD dementia.
- Traditional symptomatic drugs remain limited: AChE inhibitors and memantine can improve symptoms, but they cannot alter disease course; the paper also notes the donepezil transdermal patch (Adlarity) was FDA-approved in 2022 and showed fewer gastrointestinal adverse events than oral administration.
Methods
- This is a narrative review of recent literature on AD mechanisms, biomarkers, clinical trials, and drug-development strategies.
- The paper synthesizes prior findings across mechanistic hypotheses, biomarker studies, clinical-trial reports, and preclinical/early-stage drug examples rather than presenting a new dataset.
- Its analysis is primarily descriptive and integrative, organizing the field by disease mechanism, diagnostic approach, and therapeutic modality.
Limitations
- The paper states that no unified theory explains AD and that the interplay among pathological aspects requires further elucidation and validation.
- It notes that the high failure rate of clinical trials limits validation of hypotheses and that the long-term efficacy and safety of newer drugs such as aducanumab and lecanemab still need further study.
- Evident from the text: much of the drug-development discussion is based on preclinical studies, animal models, or early-phase trials, so many proposed strategies remain unconfirmed in larger human studies.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
187 Valid · 4 Not valid · 68 Not checked · 29 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, recent approvals of aducanumab (1) and lecanemab (2) by the Food and Drug Administration (FDA) present the potential in disrease-modifying effects.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Abstract
What the sources say
- Not matchedcites [1] WHO. A blueprint for dementia research. Geneva: World Health Organization (2022).
Its entry has no title and year that we can search by.
- Disputedcites [2] Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021). 33986301 10.1038/s41572-021-00269-y PMC8574196 sourceExperimental — accuracy not yet measured
The paper describes aducanumab as being considered by the FDA, not approved, and lecanemab as being in late-stage trials. It discusses possible clinical benefit from anti-amyloid therapies but says their future role remains uncertain. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Proteomic studies found elevated C1q levels in MCI and AD groups, and increased CatB concentration in CSF Aβ42-positive cases.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Clinical trials of AD > Biomarkers for AD diagnosis
What the sources say
- Partly supportedcites [383] Yuyama, K. et al. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis. Brain 147, 627–636 (2023). 10.1093/brain/awad361 PMC10834236 38071653 sourceExperimental — accuracy not yet measured
The section “Elevated CatB levels in CSF and plasma extracellular vesicles during amyloid pathogenesis” reports significantly higher CSF extracellular-vesicle CatB in amyloid-positive than amyloid-negative groups. The claim omits the extracellular-vesicle qualifier; the reported increase is not established for CatB in CSF generally. Page numbers are not provided in our copy. (LLM, conf=0.85)
- Disputedcites [384] Chatterjee, M. et al. C1q is increased in cerebrospinal fluid‐derived extracellular vesicles in Alzheimer’s disease: A multi‐cohort proteomics and immuno‐assay validation study. Alzheimers Dement. 19, 4828–4840 (2023). 37023079 10.1002/alz.13066 sourceExperimental — accuracy not yet measured
Section 3.2.3 (page unavailable) reports that cathepsin B (CTSB) was significantly decreased in CSF-derived extracellular vesicles from AD patients compared with controls. It also reports no difference in CTSB levels in neat CSF between those groups, not an increase. The passage does not report a separate result for Aβ42-positive cases. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“New drugs, including sodium oligomannate (9, GV-971),54–56 aducanumab (1),57–59 lecanemab (2),60–62 and donanemab (10, currently under review for market approval),63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Introduction
What the sources say
- Not checked — no full text of the sourcecites [54] Syed, Y. Y. Sodium Oligomannate: First Approval. Drugs 80, 441–444 (2020). 32020555 10.1007/s40265-020-01268-1 source
- Supportedcites [55] Wang, T. et al. A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimers Res. Ther. 12, 110 (2020). 32928279 10.1186/s13195-020-00678-3 PMC7489025 source
The citation attached to this paper concerns sodium oligomannate (GV-971), not the other named drugs. The Background contrasts drugs that do not slow AD pathology with disease-modifying approaches, and the Discussion describes GV-971 acting on Aβ aggregation and neuroinflammation. This supports the claim that it aims to intervene in disease progression; the claim does not say that it has been proven to do so. (LLM, conf=0.85)
- Supportedcites [56] Xiao, S. et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res. Ther. 13, 62 (2021). 33731209 10.1186/s13195-021-00795-7 PMC7967962 source
The citation to this paper is attached to sodium oligomannate (GV-971), not the other drugs in the sentence. The Discussion says GV-971’s proposed effects on AD pathology may delay disease progression, while noting that its mechanism requires further investigation; this supports the claim that it aims to intervene in progression, rather than establishing that it does so. (LLM, conf=0.90)
- Supportedcites [57] Cummings, J. & Salloway, S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 18, 531–533 (2022). 34314093 10.1002/alz.12444 PMC8792094 source
The citation attached to this source follows “aducanumab,” so the other named drugs are not attributed to it. The Additional information section describes aducanumab as addressing the underlying pathophysiology of AD, and the Abstract describes its expected outcome as slowing decline, while noting uncertainty about clinical benefit. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [58] Dhillon, S. Aducanumab: First Approval. Drugs 81, 1437–1443 (2021). 34324167 10.1007/s40265-021-01569-z source
- Supportedcites [59] Behl, T. et al. “Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle. Biomed. Pharmacother.148, 112746 (2022). 35231697 source
The citation is attached to aducanumab, not to the other drugs listed. Section 2 calls aducanumab a disease-modifying agent for Alzheimer’s disease and distinguishes it from treatments that do not change or retard disease progression. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [60] Larkin, H. D. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA 329, 363 (2023). 36652625 10.1001/jama.2022.24494 source
- Not checked — no full text of the sourcecites [61] Harris, E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA 330, 495 (2023). 37466999 source
- Supportedcites [62] van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023). 36449413 10.1056/NEJMoa2212948 source
The citation to this paper is attached to lecanemab, not the other drugs in the list. The introduction (p. 10) describes lecanemab as an anti-amyloid antibody being tested for early Alzheimer’s disease, and the conclusion (p. 16) reports moderately less clinical decline than with placebo. This supports describing it as aiming to modify disease progression, without claiming that long-term efficacy is established. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The accumulation of Aβ is a hallmark pathological feature in both extensively studied autosomal dominant AD and sporadic late-onset AD patients.110”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Mechanisms of AD > Amyloid hypothesis
What the sources say
- Supportedcites [110] Morris, J. C. et al. Autosomal dominant and sporadic late onset Alzheimer’s disease share a common in vivo pathophysiology. Brain 145, 3594–3607 (2022). 35580594 10.1093/brain/awac181 PMC9989348 source
The Introduction identifies cerebral Aβ accumulation as a molecular biomarker of Alzheimer’s disease and compares it in autosomal dominant AD and sporadic late-onset AD. The Abstract reports amyloid accumulation in both groups, though it was greater after symptomatic onset in the autosomal dominant group. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nonetheless, pathological changes in the brain begin during the preclinical stage, decades before clinical symptoms.”
§ Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies > Introduction
What the sources say
- Supportedcites [4] 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 19, 1598–1695 (2023). 36918389 source
Section 2.4.1 describes brain changes in the preclinical phase before symptoms develop. Section 2.9 states that Alzheimer's disease begins 20 years or more before symptom onset, supporting the claimed timescale. (LLM, conf=0.92)
- Supportedcites [20] Lloret, A. et al. When does Alzheimer’s disease really start? The role of biomarkers. Int J. Mol. Sci. 20, 5536 (2019). 31698826 10.3390/ijms20225536 PMC6888399 source
Section 2 describes a preclinical stage with pathological brain changes and no evident clinical symptoms. Section 4 states that these lesions can begin decades before the earliest symptoms, while a person is still cognitively normal. (LLM, conf=0.94)
- Supportedcites [21] Porsteinsson, A. P. et al. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J. Prev. Alzheimers Dis. 8, 371–386 (2021). 34101796 source
The Introduction describes preclinical Alzheimer’s disease as an asymptomatic stage with evidence of pathology and states that amyloid plaques typically appear about 20 years before cognitive impairment. “The importance of an early diagnosis” explicitly says the pathological hallmarks can be detected decades before symptoms. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
123 more claims · 79 with their cited sources checked
Create a free account to see all 288 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 135
- Probably not a substantial claim. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau hyperphosphorylation disrupts microtubule stability, promotes intraneuronal aggregates, synaptic dysfunction, and neuronal loss [5,6].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ aggregation into oligomers, fibrils, and senile plaques initiates a neurotoxic cascade, including tau hyperphosphorylation, mitochondrial dysfunction, and neuroinflammation [5].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During this phase, NPs designed to target Aβ plaques—a key feature of AD—as well as anti-inflammatory pathways, have shown higher bioavailability and effectiveness [80, 144].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pathophysiological process of AD is multifaceted, involving several key hypotheses: the cholinergic, glutamatergic, amyloid, tau protein, inflammatory, microbiota–gut–brain axis, oxidative stress, metal ion, and abnormal autophagy hypotheses, as shown in the summary of AD pathophysiology in Figure 1 [8].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Dysregulated processing of amyloid precursor protein (APP) generates toxic Aβ species, triggering oxidative stress, mitochondrial dysfunction, calcium dysregulation, and neuroinflammation [5].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–400 of 656
Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol
Wang, H., Kulas, J. A., Wang, C., Holtzman, D. M., Ferris, H. A., & Hansen, S. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102191118 · Cited by 301 · cited 1×
“278 Additionally, different APOE isoforms have varying impacts on A β pathology.”
BackgroundMachine learning identifies candidates for drug repurposing in Alzheimer’s disease
Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21330-0 · Cited by 299
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297 · cited 2×
“481 When A β antibodies, such as bapineuzumab ( 31 ), did not yield signi fi cant therapeutic effects, research shifted towards inhibiting the formation of A β .”
Backgroundvan Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
Synthesis and Pharmacology of Galantamine
Marco-Contelles, J., do Carmo Carreiras, M., Rodríguez, C., Villarroya, M., & García, A. G. (2006) · Chemical Reviews · doi:10.1021/cr040415t · Cited by 293
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293
Activation of innate immune cGAS-STING pathway contributes to Alzheimer’s pathogenesis in 5×FAD mice
Xie, X., Ma, G., Li, X., Zhao, J., Zhao, Z., & Zeng, J. (2023) · Nature Aging · doi:10.1038/s43587-022-00337-2 · Cited by 292 · cited 1×
“253,254 254 – 256 A recent study using a special 3D human neuroimmune axis model explored the interactions between in fi ltrative peripheral immune cells and innate immune cells in AD.”
BackgroundThe neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291 · cited 1×
“481 When A β antibodies, such as bapineuzumab ( 31 ), did not yield signi fi cant therapeutic effects, research shifted towards inhibiting the formation of A β .”
BackgroundMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288 · cited 1×
“340 Furthermore, the increased production of in fl ammatory mediators like TNF-α and the activation of stress kinases such as JNK, PKR, and IKK could promote the inhibitory serine phosphorylation of IRS-1, down-regulate insulin signaling in the brain, and induce AD neurological dysfunction.”
BackgroundDubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S., & Cummings, J. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01314-6 · Cited by 288
Copper and Zinc Dysregulation in Alzheimer’s Disease
Sensi, S. L., Granzotto, A., Siotto, M., & Squitti, R. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.001 · Cited by 285 · cited 2×
“205 When metals are sequestered in protein deposits, it may initiate a cascade of ROS production and accentuate toxicity.”
BackgroundThe amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284 · cited 3×
“78,111,112 115 However, FAD mutations are not necessarily linked to an increase in A β 42 levels or an elevation of A β 42 /A β 40 ratio.”
BackgroundPROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · cited 1×
“…such as selective inhibitors, 67 dual-target inhibitors, 68,69 allosteric modulators, 70,71 covalent inhibitors, 72 proteolysis-targeting chimeras (PROTACs) 73 and protein-protein interaction (PPI) modulators, 74,75 aiming for more effective clinical translation from outcomes of research.”
BackgroundPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J., & Tsai, L.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4305-10.2010 · Cited by 281
Calcium Dynamics as a Machine for Decoding Signals
Giorgi, C., Danese, A., Missiroli, S., Patergnani, S., & Pinton, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.002 · Cited by 281
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
Chandra, S., Sisodia, S. S., & Vassar, R. J. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00595-7 · Cited by 278
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
Cholesterol and the Biology of Alzheimer's Disease
Wolozin, B. (2004) · Neuron · doi:10.1016/s0896-6273(03)00840-7 · Cited by 275 · cited 1×
“276,277 With the assistance of cholesterol transporter APOE, astrocyte-derived cholesterol could be transferred to neuronal membranes, regulating cholesterol-dependent lipid clusters (also known as lipid rafts) on neurons to promote A β generation.”
BackgroundThe path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265
Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease
Reddy, P. H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.042 · Cited by 264
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260 · cited 2×
“544,553 The respective optimized derivatives of BQCA ( 53 ) and PF06764427 ( 54 ), compounds 55 .”
BackgroundWang, Q., Davis, P. B., Gurney, M. E., & Xu, R. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12296 · Cited by 257
Brain PET in Suspected Dementia: Patterns of Altered FDG Metabolism
Brown, R. K. J., Bohnen, N. I., Wong, K. K., Minoshima, S., & Frey, K. A. (2014) · RadioGraphics · doi:10.1148/rg.343135065 · Cited by 256
Mitochondria and Calcium in Alzheimer’s Disease: From Cell Signaling to Neuronal Cell Death
Calvo-Rodriguez, M., & Bacskai, B. J. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.004 · Cited by 254 · cited 1×
“296,297 Impairments in mitochondrial fi ssion and fusion mechanisms, as well as mitophagy, are also areas of concern in AD.”
BackgroundPhysiology and Pathology of Calcium Signaling in the Brain
Kawamoto, E. M., Vivar, C., & Camandola, S. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00061 · Cited by 249 · cited 1×
“310,311 Additionally, plasma membrane calcium ATPases (PMCA), the sarco/ER calcium ATPase (SERCA), the sodium-calcium exchangers (NCX), and Ca 2 + - binding proteins also regulate cytosolic calcium concentration.”
BackgroundUnger, M. S., Li, E., Scharnagl, L., Poupardin, R., Altendorfer, B., Mrowetz, H., Hutter-Paier, B., Weiger, T. M., Heneka, M. T., Attems, J., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.070 · Cited by 248
Moonen, S., Koper, M. J., Van Schoor, E., Schaeverbeke, J. M., Vandenberghe, R., von Arnim, C. A. F., Tousseyn, T., De Strooper, B., & Thal, D. R. (2023) · Acta Neuropathologica · doi:10.1007/s00401-022-02528-y · Cited by 248
Tau Proteins and Tauopathies in Alzheimer’s Disease
Chong, F. P., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0574-1 · Cited by 246 · cited 1×
“156,157 This process leads to the detachment of tau protein from microtubules, followed by conformational changes and mislocalization, accumulation of tau oligomers, paired helical fi laments (PHFs), and NFTs within the cell body and dendrites.”
BackgroundMitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
Mary, A., Eysert, F., Checler, F., & Chami, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01631-6 · Cited by 244 · cited 1×
“306 The accumulation of A β and increased p-tau, synaptic dysfunction, in turn, negatively regulate mitophagic activity, accelerating the pathological progression of AD.”
BackgroundAdvances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241 · cited 2×
“366 368 However, sMRI and ( 18 FDG)-PET indicate neuro-degeneration or neuronal injury in the AT(N) framework with limitations in speci fi cally diagnosing AD.”
BackgroundTargeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Wang, Z.-H., Xiang, J., Liu, X., Yu, S. P., Manfredsson, F. P., Sandoval, I. M., Wu, S., Wang, J.-Z., & Ye, K. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.054 · Cited by 238
Self-citationLuo, H.-B., Xia, Y.-Y., Shu, X.-J., Liu, Z.-C., Feng, Y., Liu, X.-H., Yu, G., Yin, G., Xiong, Y.-S., Zeng, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417548111 · Cited by 236
Self-citationResende, R., Ferreiro, E., Pereira, C., & Resende de Oliveira, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.036 · Cited by 235
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232 · cited 1×
“The observed changes in the inhibitory neurotransmitter system, exempli fi ed by γ -aminobutyric acid, 212 and the potential for excitotoxicity to alter cognitive levels earlier than A β and tau pathologies, 209 suggest that excitotoxicity might hold greater potential in AD treatment.”
BackgroundApolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms
Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231 · cited 2×
“121 – 124 Moreover, other genetic risk factors, 125,126 cardiovascular health issues (such as diabetes, hypercholesterolemia), and lifestyle factors (such as diet and sleep) 127 have also been extensively studied in recent years for their relationship with A β metabolism in SAD.”
BackgroundNew approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226 · cited 3×
“5,6 Clinically, the primary hallmark of AD is amnestic cognitive impairment.”
BackgroundCholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226 · cited 2×
“275,276 The connection between cholesterol and A β may be related to lipid rafts, which are cholesterol-rich microdomains on the plasma membrane.”
BackgroundTargeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225 · cited 2×
“261 – 263 A key factor affecting lysosomal function is the pH controlled by the vacuolar (H + )-ATPase (V-ATPase), which uses the energy from ATP hydrolysis to drive H + from the cytoplasm into the lysosome.”
BackgroundXiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224 · cited 1×
“554 and 56, 555 require further in vitro and in vivo studies to evaluate their pharmacokinetic properties and allosteric modulation effects.”
BackgroundSelf-citationDysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222 · cited 1×
“507,512 Compound 38 , incorporating cap group of melatonin and ferulic acid, enhanced HDAC6 selectivity while providing signi fi cant antioxidant capacity, alleviating spatial working and non-spatial long-term memory de fi cits in A β 25-35 -injected mice at lower doses.”
BackgroundDifferential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation
White, J. A., Manelli, A. M., Holmberg, K. H., Van Eldik, L. J., & LaDu, M. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.013 · Cited by 221
Tong, L., Balazs, R., Thornton, P. L., & Cotman, C. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5463-03.2004 · Cited by 221
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220 · cited 1×
“153,154 It hosts numerous phosphorylation sites across its N-terminal region, C-terminal region, and repeat region, which are regulated by a balance of various kinases and phosphatases to maintain normal neuronal physiological functions.”
BackgroundWilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219 · cited 1×
“638,639 Some variants associated with AD, such as the TREM2 variant R47H, may potentially diminish the binding or internalization of TREM2 with ligands such as APOE-A β complexes, APOE, phospholipids, and A β .”
BackgroundRole of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Lecca, D., Jung, Y. J., Scerba, M. T., Hwang, I., Kim, Y. K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S., Liu, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12610 · Cited by 218
Self-citationCombination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Jorfi, M., Park, J., Hall, C. K., Lin, C.-C. J., Chen, M., von Maydell, D., Kruskop, J. M., Kang, B., Choi, Y., Prokopenko, D., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01415-3 · Cited by 214
Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.001 · Cited by 212
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212 · cited 1×
“355,356 – 359 Dysfunction of the BBB includes disruption of BBB integrity (or BBB leakage), changes in BBB transport functions, reduced cerebral blood fl ow, and neuroin fl ammation.”
BackgroundLiu, Y., Li, Y., Wang, Y., Lin, C., Zhang, D., Chen, J., Ouyang, L., Wu, F., Zhang, J., & Chen, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01310-7 · Cited by 210 · cited 1×
“541 Although these approaches facilitate drug design on a technical level, relying on a limited set of known SARs for pharmacophores may somewhat limit the structural diversity of the drugs and narrow the range of targets.”
BackgroundSelf-citationCoen, K., Flannagan, R. S., Baron, S., Carraro-Lacroix, L. R., Wang, D., Vermeire, W., Michiels, C., Munck, S., Baert, V., Sugita, S., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201201076 · Cited by 208
Allosteric small-molecule kinase inhibitors
Wu, P., Clausen, M. H., & Nielsen, T. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.002 · Cited by 204 · cited 1×
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundMitochondrial dynamics and transport in Alzheimer's disease
Flannery, P. J., & Trushina, E. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.009 · Cited by 202 · cited 1×
“283,301 Fragmented mitochondria signi fi cantly obstruct mitophagy in AD, where PINK1/parkin-regulated mito-phagy is a focal point of current research.”
BackgroundOxidative Stress in Alzheimer’s Disease: Are We Connecting the Dots?: Miniperspective
Rosini, M., Simoni, E., Milelli, A., Minarini, A., & Melchiorre, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400970m · Cited by 201 · cited 1×
“197 For example, oxidative stress modulates the process of APP and the activity of secretases, thereby promoting the amyloid pathway.”
BackgroundDrug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Chen, L.-L., Fan, Y.-G., Zhao, L.-X., Zhang, Q., & Wang, Z.-Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106301 · Cited by 200
Self-citationAutophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199 · cited 1×
“261 – 263 A key factor affecting lysosomal function is the pH controlled by the vacuolar (H + )-ATPase (V-ATPase), which uses the energy from ATP hydrolysis to drive H + from the cytoplasm into the lysosome.”
BackgroundBlazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197 · cited 3×
“75,579 582 Thus, disrupting these interactions may block some critical signaling pathways and potentially mitigate the pathological process of AD.”
BackgroundThe Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 197
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197 · cited 1×
“83,423 The disparity in drug performance between preclinical and human trials has driven the evolution of animal models.”
BackgroundWang, Y., Lin, Y., Wang, L., Zhan, H., Luo, X., Zeng, Y., Wu, W., Zhang, X., & Wang, F. (2020) · Aging · doi:10.18632/aging.104104 · Cited by 196
Roy, R. G., Mandal, P. K., & Maroon, J. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00486 · Cited by 194
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Structural basis of γ-secretase inhibition and modulation by small molecule drugs
Yang, G., Zhou, R., Guo, X., Yan, C., Lei, J., & Shi, Y. (2021) · Cell · doi:10.1016/j.cell.2020.11.049 · Cited by 189
Sodium Oligomannate: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187 · cited 2×
“544,553 The respective optimized derivatives of BQCA ( 53 ) and PF06764427 ( 54 ), compounds 55 .”
BackgroundNovak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Recognition of the Amyloid Precursor Protein by Human gamma-secretase: 6iyc
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6iyc/pdb · Cited by 185
Systematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184 · cited 1×
“253,254 254 – 256 A recent study using a special 3D human neuroimmune axis model explored the interactions between in fi ltrative peripheral immune cells and innate immune cells in AD.”
BackgroundAntidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179 · cited 1×
“334,335 The PI3K-Akt pathway is a crucial component of insulin signaling, and in AD brains, there is observed a decrease in IRS-associated PI3K activity and reduced phosphorylation of Akt kinase.”
BackgroundGuidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (n.d.) · Kölner Universitäts PublikationsServer (Universität zu Köln) · doi:10.13016/m2d6kq-yctj · Cited by 178
Association of COVID-19 with New-Onset Alzheimer’s Disease
Wang, L., Davis, P. B., Volkow, N. D., Berger, N. A., Kaelber, D. C., & Xu, R. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220717 · Cited by 178
Eckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177
Impaired insulin signalling and allostatic load in Alzheimer disease
De Felice, F. G., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 177 · cited 2×
“330 Insulin signaling Insulin regulates glucose metabolism, neuronal growth and survival, synaptic plasticity, and cognition, 331 – 333 functions closely linked to two main insulin signaling pathways: phosphatidylinositol 3-kinase (PI3K)-Akt and Ras/Raf-MAPK.”
BackgroundDavis, K. L., & Powchick, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90526-x · Cited by 177 · cited 2×
“For instance, the selective GSK3 β inhibitor OCM-51 ( 36 ) could achieve a bene fi cial balance between reducing tau phosphorylation and preventing overactivation of the β -catenin signaling pathway at appropriate doses.”
Chen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00446 · Cited by 175 · cited 2×
“97,99 It has been observed that cholinergic neurons in the NBM region are particularly susceptible to degeneration and loss in AD.”
BackgroundPeriodontal microorganisms and Alzheimer disease – A causative relationship?
Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174 · cited 1×
“594,595 598 Research of both HSV1-infected mice and AD mouse models has revealed the gene MAM domain containing 2 (MAMDC2) exhibits signi fi cant expression in microglia, which results in high levels of I-IFNs to enhance antiviral responses in HSV1-infected mice and neuroin fl ammation in the AD…”
BackgroundNGF and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons
Matrone, C., Ciotti, M. T., Mercanti, D., Marolda, R., & Calissano, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806133105 · Cited by 169
Zhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168 · cited 1×
“260 Lysosomal dysfunction Lysosomes rely on a rich array of acidic hydrolases to selectively degrade and recycle both intracellular and extracellular materials, playing a crucial role in maintaining cellular homeostasis.”
BackgroundSelf-citationSignaling pathway cross talk in Alzheimer’s disease
Godoy, J. A., Rios, J. A., Zolezzi, J. M., Braidy, N., & Inestrosa, N. C. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-23 · Cited by 164 · cited 1×
“282,285 More-over, AD pathological biomarkers could directly impact mitochondrial function, creating a vicious cycle.”
BackgroundGene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164 · cited 1×
“They may achieve this by altering biological pathways and genetic susceptibility, 23,84 – 86 making it challenging to pinpoint a direct cause of clinical pathology in AD.”
BackgroundMechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders
Huang, Y., Liu, B., Sinha, S. C., Amin, S., & Gan, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00672-x · Cited by 164 · cited 1×
“253,254 254 – 256 A recent study using a special 3D human neuroimmune axis model explored the interactions between in fi ltrative peripheral immune cells and innate immune cells in AD.”
BackgroundDeregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria
Gowda, P., Reddy, P. H., & Kumar, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101529 · Cited by 163 · cited 2×
“282,283 Observations in AD-af fl icted brains of regionally reduced glucose metabolism and alterations in several mitochondrial enzyme activities suggest mitochondrial dysfunction.”
BackgroundBrain cell type-specific cholesterol metabolism and implications for learning and memory
Li, D., Zhang, J., & Liu, Q. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.01.002 · Cited by 163
Self-citationBossy, B., Petrilli, A., Klinglmayr, E., Chen, J., Lütz-Meindl, U., Knott, A. B., Masliah, E., Schwarzenbacher, R., & Bossy-Wetzel, E. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100552 · Cited by 161 · cited 1×
“…levels of proteins related to fi ssion/fusion processes (such as Opa1, Drp1, MFN1/2, Fis1) 298 and post-translational modi fi cations of Drp1 299,300 may bias mitochondria towards excessive fi ssion, increasing mitochondrial fragmentation, leading to damage in mitochondrial energy biology and…”
BackgroundCholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161
Litvinchuk, A., Suh, J. H., Guo, J. L., Lin, K., Davis, S. S., Bien-Ly, N., Tycksen, E., Tabor, G. T., Remolina Serrano, J., Manis, M., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.10.023 · Cited by 161 · cited 1×
“280 Furthermore, activation of the in fl ammation-related NLRP3 in fl ammasome signaling pathway in different types of neural cells was closely associated with high cholesterol load, which triggered neuroprotective properties in activated microglia but promoted oxidative stress in neurons, further…”
BackgroundBasheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
Apolipoprotein E and Alzheimer's disease
Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 156 · cited 1×
“121 – 124 Moreover, other genetic risk factors, 125,126 cardiovascular health issues (such as diabetes, hypercholesterolemia), and lifestyle factors (such as diet and sleep) 127 have also been extensively studied in recent years for their relationship with A β metabolism in SAD.”
BackgroundAβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 155
Anekonda, T. S., Quinn, J. F., Harris, C., Frahler, K., Wadsworth, T. L., & Woltjer, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.020 · Cited by 155
Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer’s Disease
Akıncıoğlu, H., & Gülçin, İ. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200103100521 · Cited by 155
Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155 · cited 1×
“487 While immunotherapy appears to be the most advanced therapeutic strategy, primarily targeting traditional targets such as A β and tau, a noticeable paradigm shift is occurring toward small-molecule therapeutic modalities.”
BackgroundSelf-citationHigh‐affinity interactions and signal transduction between Aβ oligomers and TREM 2
Lessard, C. B., Malnik, S. L., Zhou, Y., Ladd, T. B., Cruz, P. E., Ran, Y., Mahan, T. E., Chakrabaty, P., Holtzman, D. M., Ulrich, J. D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809027 · Cited by 154
Alber, J., Goldfarb, D., Thompson, L. I., Arthur, E., Hernandez, K., Cheng, D., DeBuc, D. C., Cordeiro, F., Provetti‐Cunha, L., den Haan, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12006 · Cited by 154
Boyd, R. J., Avramopoulos, D., Jantzie, L. L., & McCallion, A. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02584-x · Cited by 153
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152 · cited 1×
“510,511 Their selectivity often involves strong hydrophobic interactions between the cap group and a large surface area on HDAC6, known as the “ L1 loop pocket ” .”
BackgroundDissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · cited 1×
“366,371 Studies have reported that amyloid PET exhibits 90% sensitivity and speci fi city in diagnosing AD, and tau PET can speci fi cally identify AD dementia from other neurodegenerative diseases, showing higher diagnostic accuracy than MRI markers.”
BackgroundSelf-citationGenomics of Alzheimer Disease: A Review
Rosenberg, R. N., Lambracht-Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 146
Liu, C.-C., Wang, N., Chen, Y., Inoue, Y., Shue, F., Ren, Y., Wang, M., Qiao, W., Ikezu, T. C., Li, Z., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01640-9 · Cited by 146
Regulation of lysosomal ion homeostasis by channels and transporters
Xiong, J., & Zhu, M. X. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5090-x · Cited by 141 · cited 1×
“264,265 In AD, lysosomal acidi fi cation de fi cits may weaken the clearance of A β , ultimately leading to the accumulation of extracellular A β plaques.”
BackgroundAlzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Bucci, M., Chiotis, K., Nordberg, A., & Initiative, F. T. A. D. N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01263-2 · Cited by 140
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease
Uddin, M. S., Yu, W. S., & Lim, L. W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101417 · Cited by 136
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Hampel, H., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 135
Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135
Wang, S., Wang, L., Qin, X., Turdi, S., Sun, D., Culver, B., Reiter, R. J., Wang, X., Zhou, H., & Ren, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0171-5 · Cited by 135
Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases
Liu, Y., & Zhu, X. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0092-6 · Cited by 132 · cited 1×
“324 – 326 Under the in fl uence of A β , the expression of some MAM-related proteins, such as IP3Rs and VDAC1, is signi fi cantly increased, 325,327,328 leading to mitochondrial Ca 2 + overload, inhibition of normal ATP synthesis, and potential release of apoptotic signals.”
BackgroundInvestigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131 · cited 1×
“4,20,21 Therefore, it ’ s crucial to concentrate on the preclinical and MCI stages, where early intervention and management of modi fi able risk factors could potentially lower the risk of onset or delay the progression of disease.”
BackgroundArtificial intelligence for biomarker discovery in Alzheimer's disease and dementia
Winchester, L. M., Harshfield, E. L., Shi, L., Badhwar, A., Khleifat, A. A., Clarke, N., Dehsarvi, A., Lengyel, I., Lourida, I., Madan, C. R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13390 · Cited by 130
Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0431-6 · Cited by 129
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
The Neurovascular Unit: Effects of Brain Insults During the Perinatal Period
Bell, A. H., Miller, S. L., Castillo-Melendez, M., & Malhotra, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01452 · Cited by 127
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127 · cited 1×
“355,356 – 359 Dysfunction of the BBB includes disruption of BBB integrity (or BBB leakage), changes in BBB transport functions, reduced cerebral blood fl ow, and neuroin fl ammation.”
BackgroundAntiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
The Alzheimer’s disease drug development landscape
van Bokhoven, P., de Wilde, A., Vermunt, L., Leferink, P. S., Heetveld, S., Cummings, J., Scheltens, P., & Vijverberg, E. G. B. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00927-z · Cited by 123 · cited 1×
“435 These modalities, characterized by their simplicity, maturity, and adaptability, provide a promising avenue for emerging targets.”
BackgroundZhang, X., Garbett, K., Veeraraghavalu, K., Wilburn, B., Gilmore, R., Mirnics, K., & Sisodia, S. S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0556-12.2012 · Cited by 122 · cited 1×
“267,268 Calcium dysregulation associated with PS1 has been proposed as a potential cause of endolysosomal defects.”
BackgroundJiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00463 · Cited by 122
Majdi, A., Sadigh-Eteghad, S., Rahigh Aghsan, S., Farajdokht, F., Vatandoust, S. M., Namvaran, A., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 122
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122 · cited 1×
“Improving the selectivity of covalent inhibitors is critical and can be optimized through various means, including adjusting the reactivity and reversibility of the electrophile (warhead), 571,572 non-covalent scaffolds, dosage, etc. Relevant literature has discussed these aspects (Fig.”
BackgroundWhitwell, J. L., Graff‐Radford, J., Tosakulwong, N., Weigand, S. D., Machulda, M. M., Senjem, M. L., Spychalla, A. J., Vemuri, P., Jones, D. T., Drubach, D. A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.020 · Cited by 121 · cited 1×
“152 In recent years, there has been a heightened focus on tau deposition, including the correlation between tau deposition, brain atrophy, and glucose metabolism in both typical and atypical AD, 167,168 as well as the effects of tau deposition at the molecular and cellular levels.”
BackgroundMultitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies?
Ferreira, M. E. S., de Vasconcelos, A. S., Vilhena, T. D. C., da Silva, T. L., Barbosa, A. D. S., Gomes, A. R. Q., Dolabela, M. F., & Percário, S. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0157-y · Cited by 118 · cited 1×
“198 However, the ef fi cacy of antioxidants in clinical trials for AD remains uncertain.”
BackgroundOld and new acetylcholinesterase inhibitors for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216972 · Cited by 117
Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies
Nicolo, B. D., Cataldi-Stagetti, E., Diquigiovanni, C., & Bonora, E. (2023) · Antioxidants · doi:10.3390/antiox12020353 · Cited by 117 · cited 1×
“290 A β may increase cytosolic calcium levels and impair mitochondrial calcium buffering functions through various pathways including plasma membrane receptors and calcium channels, 291 enhanced ER calcium release, 292 and the mitochondrial inner membrane calcium channel MCU.”
BackgroundLo, C. H., & Zeng, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00362-0 · Cited by 117
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116 · cited 3×
“109,170 However, the side effects associated with targeting β - and γ -secretases arise because these enzymes have a wide range of substrates that are vital in other physiological processes.”
BackgroundAdvance of sporadic Alzheimer's disease animal models
Zhang, L., Chen, C., Mak, M. S., Lu, J., Wu, Z., Chen, Q., Han, Y., Li, Y., & Pi, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21624 · Cited by 116
Microbial involvement in Alzheimer disease development and progression
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116 · cited 2×
“214 Some animal studies suggested that Porphyromonas gingivalis could translocate to the brain, closely linked to the deposition of A β and tau and the occurrence of neuroin fl ammation.”
BackgroundInsights into amyloid-β-induced mitochondrial dysfunction in Alzheimer disease
Wang, X., Su, B., Perry, G. L., Smith, M. A., & Zhu, X. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.09.007 · Cited by 115
Emerging risk of environmental factors: insight mechanisms of Alzheimer’s diseases.
Rahman, M. A., Rahman, M. S., Uddin, M. J., Mamum-Or-Rashid, A. N. M., Pang, M.-G., & Rhim, H. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-08243-z · Cited by 115 · cited 1×
“They may achieve this by altering biological pathways and genetic susceptibility, 23,84 – 86 making it challenging to pinpoint a direct cause of clinical pathology in AD.”
BackgroundXu, J., Mao, C., Hou, Y., Luo, Y., Binder, J. L., Zhou, Y., Bekris, L. M., Shin, J., Hu, M., Wang, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111717 · Cited by 115
Moreira, F. T. C., Sale, M. G. F., & Di Lorenzo, M. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.104 · Cited by 114 · cited 1×
“108 In summary, the cholinergic hypothesis, as a well-established and classic theory, has signi fi cantly advanced the early research and drug development for AD.”
BackgroundAlzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs
Thakral, S., Yadav, A., Singh, V., Kumar, M., Kumar, P., Narang, R., Sudhakar, K., Verma, A., Khalilullah, H., Jaremko, M., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101960 · Cited by 113 · cited 2×
“476 Repurposed drugs include nilvadipine ( 29 ), a calcium channel blocker for the treatment of hypertension, and pioglitazone ( 30 ), a drug initially developed for diabetes.”
BackgroundMethodBiomarkers for Alzheimer’s Disease in the Current State: A Narrative Review
Gunes, S., Aizawa, Y., Sugashi, T., Sugimoto, M., & Rodrigues, P. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094962 · Cited by 112
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene
Magusali, N., Graham, A. C., Piers, T. M., Panichnantakul, P., Yaman, U., Shoai, M., Reynolds, R. H., Botia, J. A., Brookes, K. J., Guetta-Baranes, T., et al. (2021) · Brain · doi:10.1093/brain/awab337 · Cited by 111
O'Bryant, S. E., Petersen, M., Hall, J., Johnson, L. A., & for the HABS‐HD Study Team (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12647 · Cited by 110 · cited 1×
“393 For example, coexisting α Syn pathology in AD correlates with lower CSF P-tau181 and NG levels, 394 while comorbidity like hypertension lowers plasma A β concentration but increases plasma P-tau181 and P-tau217 levels.”
BackgroundLecanemab Gains FDA Approval for Early Alzheimer Disease
Larkin, H. D. (2023) · JAMA · doi:10.1001/jama.2022.24490 · Cited by 110 · cited 2×
“33,53 New drugs, including sodium oligomannate ( 9 , GV-971), 54 – 56 aducanumab ( 1 ), 57 – 59 lecanemab ( 2 ), 60 – 62 and donanemab ( 10 , currently under review for market approval), 63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
BackgroundThe benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Bateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109
New perspectives on the basal forebrain cholinergic system in Alzheimer’s disease
Berry, A. S., & Harrison, T. M. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105192 · Cited by 109
Perspectives and challenges in patient stratification in Alzheimer’s disease
Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L. T., Viñuela, F., & Traber, M. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01055-y · Cited by 108
Feldman, H. H., Lane, R., & on behalf of the Study 304 Group (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.099424 · Cited by 107 · cited 2×
“Medications such as donepezil ( 4 ), 41 – 43 rivastig-mine ( 5 ), 44,45 galantamine ( 6 ), 46 – 48 memantine ( 7 ), 49,50 and namzaric ( 8 ) 51,52 have been employed in clinical settings.”
BackgroundViayna, E., Coquelle, N., Cieslikiewicz-Bouet, M., Cisternas, P., Oliva, C. A., Sánchez-López, E., Ettcheto, M., Bartolini, M., De Simone, A., Ricchini, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01775 · Cited by 106 · cited 1×
“530 Given the elevated activity of monoamine oxidase-B (MAO-B) observed in AD, dual inhibition of AChE and MAO-B holds promise for synergistic effects on cholinergic system recovery and A β plaque formation, along with potential bene fi ts in alleviating oxidative stress injury.”
BackgroundHe, Q., Liu, J., Lan, J.-S., Ding, J., Sun, Y., Fang, Y., Jiang, N., Yang, Z., Sun, L., Jin, Y., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.010 · Cited by 105 · cited 1×
“531 Ladostigil ( 46 ), an AChE/MAO-B inhibitor developed through a pharmacophore fusion strategy, 532 has completed a clinical phase II trial (NCT01429623).”
BackgroundRole of Microglial Cells in Alzheimer’s Disease Tau Propagation
Španić, E., Langer Horvat, L., Hof, P. R., & Šimić, G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00271 · Cited by 105
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
Wong-Guerra, M., Calfío, C., Maccioni, R. B., & Rojo, L. E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161850 · Cited by 105
Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Alzheimer’s Disease—Biochemical and Psychological Background for Diagnosis and Treatment
Beata, B.-K., Wojciech, J., Kornhuber, J., Lewczuk, P., & Mroczko, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021059 · Cited by 104
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102 · cited 3×
“The toxicity mechanism of A β aggregates remains uncertain, but different perspectives exist: 77,128 A β might cause AD pathology through the loss of physiological functions during the aggregation process.”
BackgroundOmura, J. D., McGuire, L. C., Patel, R., Baumgart, M., Lamb, R., Jeffers, E. M., Olivari, B. S., Croft, J. B., Thomas, C. W., & Hacker, K. A. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7120a2 · Cited by 101
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100 · cited 1×
“575 Various reviews 574,575 have consolidated information on PROTACs with potential applications in AD.”
BackgroundSelf-citationClassics in Chemical Neuroscience: Donepezil
Brewster, J. T., Dell’Acqua, S., Thach, D. Q., & Sessler, J. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00517 · Cited by 98 · cited 1×
“519 Recently studied compounds 43 and 44 exhibited excellent performance in three behavioral tests of homozygous APPswe/PS1dE9 double transgenic mouse models and 3xTg mouse dementia models (Fig.”
BackgroundHu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96 · cited 1×
“526 527 – 529 The dual inhibitor of AChE and BuChE, compound 45 , signi fi cantly enhanced the learning and memory abilities of aged AD mice.”
BackgroundNedelec, T., Couvy-Duchesne, B., Monnet, F., Daly, T., Ansart, M., Gantzer, L., Lekens, B., Epelbaum, S., Dufouil, C., & Durrleman, S. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00275-2 · Cited by 96 · cited 2×
“22 Evidence suggests that about one-third of AD cases worldwide are closely linked to modi fi able risk factors.”
BackgroundPharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96 · cited 1×
“51 These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease, 409,411 which are instructive for designing new drugs.”
BackgroundNaeem, A., Prakash, R., Kumari, N., Ali Khan, M., Quaiyoom Khan, A., Uddin, S., Verma, S., AB Robertson, A., Boltze, J., & Shadab Raza, S. (2024) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.11.031 · Cited by 96
Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease
Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 95
Acetylcholine and Alzheimer's Disease
Perry, E. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.152.6.737 · Cited by 93 · cited 1×
“109 Despite these advancements, the limited ef fi cacy and side effects of such drugs, coupled with the presence of non-cholinergic groups in AD, 99 and non-speci fi city in these pathological features, 94 challenge the cholinergic hypothesis to fully explain the complex of AD pathology.”
BackgroundThe Gut-Brain Axis in Alzheimer’s Disease and Omega-3. A Critical Overview of Clinical Trials
La Rosa, F., Clerici, M., Ratto, D., Occhinegro, A., Licito, A., Romeo, M., Iorio, C. D., & Rossi, P. (2018) · Nutrients · doi:10.3390/nu10091267 · Cited by 93
The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology
Giuffrida, M. L., Caraci, F., De Bona, P., Pappalardo, G., Nicoletti, F., Rizzarelli, E., & Copani, A. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.2.83 · Cited by 91 · cited 1×
“The toxicity mechanism of A β aggregates remains uncertain, but different perspectives exist: 77,128 A β might cause AD pathology through the loss of physiological functions during the aggregation process.”
BackgroundTerzioglu, G., & Young-Pearse, T. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00674-9 · Cited by 91
Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system
Smajilovic, S., & Tfelt‐Hansen, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.015 · Cited by 90
Nicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Ashton, N. J., Ide, M., Zetterberg, H., & Blennow, K. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00168-1 · Cited by 89
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89 · cited 3×
“222 Microautophagy is the simplest pathway in which cytoplasmic substrates enter vesicles formed by morphological changes in lysosomal or endosomal membranes, and are ultimately degraded within the lysosome.”
BackgroundDevelopment of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88 · cited 2×
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationNEURONAL COUNTS IN BASAL NUCLEUS OF MEYNERT IN ALZHEIMER DISEASE AND IN SIMPLE SENILE DEMENTIA
Tagliavini, F., & Pilleri, G. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91462-9 · Cited by 87
Dutta, D., Jana, M., Paidi, R. K., Majumder, M., Raha, S., Dasarathy, S., & Pahan, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci161987 · Cited by 87 · cited 1×
“251 Research by Ising et al. suggests that tau proteins can activate the NLRP3 in fl ammasome, which then promotes excessive tau phosphorylation and aggregation by affecting speci fi c tau kinases and phosphatases.”
Backgroundde Dios, C., Abadin, X., Roca-Agujetas, V., Jimenez-Martinez, M., Morales, A., Trullas, R., Mari, M., & Colell, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00343-3 · Cited by 85
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Current trends in blood biomarker detection and imaging for Alzheimer’s disease
Hu, S., Yang, C., & Luo, H. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114278 · Cited by 84
Viles, J. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202215785 · Cited by 83 · cited 1×
“129,130 Soluble A β oligomers are the primary neurotoxic substances, 131 – 133 disruption of cell membrane integrity, 134 activation in in fl ammatory responses, 135,136 causes of calcium homeostasis imbalance 137 and mitochondrial dysfunction, 138 – 140 triggers in oxidative stress, 141 and damage…”
BackgroundLi, J., Sun, M., Cui, X., & Li, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710020 · Cited by 82
Drugs: A tangled web of targets
Gravitz, L. (2011) · Nature · doi:10.1038/475s9a · Cited by 81
Yu, W., Jin, H., & Huang, Y. (2021) · Clinical Science · doi:10.1042/cs20200844 · Cited by 81 · cited 1×
“329 Research has found that lysosomal acidity is also within the realm of calcium regulation, where excessive Ca 2 + released from the ER-resident RyR receptor can impair the function of lysosomal V-ATPase, causing lysosomal acidi fi cation defects, reducing lysosomal protease activity, and leading…”
BackgroundIm, E., Jiang, Y., Stavrides, P. H., Darji, S., Erdjument-Bromage, H., Neubert, T. A., Choi, J. Y., Wegiel, J., Lee, J.-H., & Nixon, R. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1925 · Cited by 80
Implications of gut and oral microbiota in neuroinflammatory responses in Alzheimer's disease
Bello-Corral, L., Gomes, L., Fernández-Fernández, J. A., Fernández-García, D., Verdejo, I. C., & Sánchez-Valdeón, L. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122132 · Cited by 79
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78 · cited 1×
“117 Apolipoprotein E (APOE), particularly the ε 4 allele, stands out as the most crucial genetic risk factor for SAD.”
BackgroundWu, X.-L., Piña-Crespo, J., Zhang, Y.-W., Chen, X.-C., & Xu, H.-X. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 77
Self-citationAnti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Research works printed but not linked: 3
- Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567–S610 (2018). 29843241 10.3233/JAD-179941 PMC6004937 · DOI · Paper page
- Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δ Inhibitors. ACS Med. Chem. Lett. 11, 1168–1174 (2020). 32550997 10.1021/acsmedchemlett.0c00028 PMC7294733 · DOI · Paper page
- Zhang, Y. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023). 37386015 10.1038/s41392-023-01484-7 PMC10310781 · DOI · Paper page
Cited by
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
Xu, W., Huang, Y., & Zhou, R. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01275-w · Cited by 295
“Continuously activated microglia may cause persistent in fl ammation, leading to neuronal damage and promoting the formation of amyloid beta (A β ) plaques [43, 44].”
Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies
Mehdizadeh, S., Mamaghani, M., Hassanikia, S., Pilehvar‐Soltanahmadi, Y., & Ertaş, Y. N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03352-8 · Cited by 150
“Traditional drug therapies, such as cholinester-ase inhibitors and N-methyl D-aspartate (NMDA) receptor antagonists, often provide symptomatic relief rather than addressing the underlying pathology, and their efficacy is limited by their inability to cross the BBB efficiently [120].”
Chen, C., Wang, G., Li, D., & Zhang, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00307-1 · Cited by 148
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies
Mallick, R., Basak, S., Chowdhury, P., Bhowmik, P., Das, R. K., Banerjee, A., Paul, S., Pathak, S., & Duttaroy, A. K. (2025) · Pharmaceuticals · doi:10.3390/ph18010104 · Cited by 122
“Solanezumab, an anti-amyloid monoclonal antibody that does not directly target cytokines, has shown promise in decreasing levels of neuroinflammatory indicators in CSF [173,174].”
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Metadata
- Authors
- Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L.
- Affiliations
- Sichuan University (CN)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Chen, Lei
- ORCID
- Wang, Jiaxing
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-23
- Volume
- 9
- Issue
- 1
- Pages
- 211-211
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11344989
- OpenAlex
- W4401806028
- Semantic Scholar
- 8ff7d224cd5f81cb22fca07098d6f0ed92abd2bf
- Cited by
- 1,138
- References
- 674
- Citations by year
- 2026: 516 · 2025: 588 · 2024: 32
- FWCI
- 335.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Keywords
- Alzheimer's disease, Alzheimer's disease pathogenesis, amyloid hypothesis, tau protein, cholinergic hypothesis, neuroinflammation, oxidative stress, microbiota-gut-brain axis
- MeSH terms
- Drug Development, Alzheimer Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.